GlassScriptPhysician profile
Sangeeth S Pai
NPI 1124021225
$3,742.73
in general payments reported to CMS, 2019-2025
25 companies · $98.03 in 2025
The $98.03 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $782 · 2021: $641 · 2022: $747 · 2023: $606 · 2025: $98.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.89 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $774.44 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $487.55 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $436.08 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.26 | 2019-2023 | |
| Pfizer INC. | $305.51 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $244.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $152.06 | 2019-2020 | |
| Glaxosmithkline, LLC. | $141.05 | 2020-2023 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $137.34 | 2021-2023 | |
| Amgen INC. | $136.03 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $108.52 | 2021-2025 | Vraylar |
| Abiomed | $99.06 | 2023 | Impella |
| Radius Health, INC. | $86.71 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $43.30 | 2022-2023 | |
| Amarin Pharma, INC. | $41.67 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.54 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $27.72 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $25.48 | 2019-2022 | |
| Astellas Pharma US INC | $22.70 | 2022 | |
| Dexcom, INC. | $18.39 | 2021 | |
| Allergan, INC. | $17.00 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Amag Pharmaceuticals, INC. | $14.29 | 2020 | |
| Ge Healthcare | $13.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sangeeth Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.